Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.
Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.
<iframe src="https://statesidedaily.com/embed/cluster/53a963011a863916a221fd441ad0b434d31e52c5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom"></iframe>
